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ISSNObjective: We estimated and compared the risk of clinically identified acquired drug
resistance under immediate initiation [the currently recommended antiretroviral ther-
apy (ART) initiation strategy], initiation with CD4þ cell count less than 500 cells/ml and
initiation with CD4þ cell count less than 350 cells/ml.
Design: Cohort study based on routinely collected data from the HIV-CAUSAL
collaboration.
Methods: For each individual, baseline was the earliest time when all eligibility criteria
(ART-naive, AIDS free, and others) were met after 1999. Acquired drug resistance was
defined using the Stanford classification as resistance to any antiretroviral drug that was
clinically identified at least 6 months after ART initiation. We used the parametric
g-formula to adjust for time-varying (CD4þ cell count, HIV RNA, AIDS, ART regimen,
and drug resistance testing) and baseline (calendar period, mode of acquisition, sex,
age, geographical origin, ethnicity and cohort) characteristics.
Results: In 50981 eligible individuals, 10% had CD4þ cell count more than 500 cells/
ml at baseline, and 63% initiated ART during follow-up. Of 2672 tests for acquired drug
resistance, 794 found resistance. The estimated 7-year risk (95% confidence interval) of
acquired drug resistance was 3.2% (2.8,3.5) for immediate initiation, 3.1% (2.7,3.3) for
initiation with CD4þ cell count less than 500 cells/ml, and 2.8% (2.5,3.0) for initiation
with CD4þ cell count less than 350 cells/ml. In analyses restricted to individuals with Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
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 328 AIDS 2018, Vol 32 No 3baseline in 2005–2015, the corresponding estimates were 1.9% (1.8, 2.5), 1.9% (1.7,
2.4), and 1.8% (1.7, 2.2).
Conclusion: Our findings suggest that the risk of acquired drug resistance is very low,
especially in recent calendar periods, and that immediate ART initiation only slightly
increases the risk. It is unlikely that drug resistance will jeopardize the proven benefits of
immediate ART initiation. Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2018, 32:327–335Keywords: comparative effectiveness, drug resistance, HIV,
parametric g-formula, when to startIntroduction
Immediate initiation of antiretroviral therapy (ART)
upon diagnosis of HIV infection results in lower risk of
serious clinical events [1,2] and virus transmission when
compared with delayed ART initiation [3,4]. Therefore,
international clinical guidelines now recommend imme-
diate ART initiation for all HIV-positive individuals,
regardless of CD4þ cell count [5–8]. A potential concern
is that the more prolonged exposure associated with
immediate initiation [9] can increase the risk of acquiring
drug resistance, which decreases virus susceptibility to
specific antiretroviral drugs or drug classes.
Estimates of the long-term risk of acquired drug resistance
under immediate ART initiation are needed to fully
understand the public health impact of the current guidelines
for ART initiation and to estimate the number of individuals
in need of second-line therapy. These estimates, however,
will need to be obtained from observational studies because
the follow-up of the completed randomized trials was
relatively short [1,2] and no other large randomized trials are
planned. Although several observational studies found that
ART initiation at high CD4þ cell counts was associated with
a lower risk of drug resistance, [10–13] these studies did not
adjust for time-varying confounders and used the date of
ART initiation, rather than the date of entry into care, as the
time origin.
Here, we estimate and compare the 7-year risks of acquired
drug resistance under immediate ART initiation and the
previously recommended CD4þ cell count-based initia-
tion strategies. To do so, we use data on HIV-positive
individuals receiving HIV care in five European countries.Methods
Study population
The HIV-CAUSAL collaboration is a consortium of
prospective HIV cohorts from Europe and the America.
All cohorts record routinely collected data in clinical
practice within settings with universal access to care. Data
collected include patient characteristics (age, sex,Copyright © 2018 Wolters Kluwer Hgeographical origin, and transmission category), use of
ART (type of regimes and dates of start and discontinua-
tion), CD4þ cell counts, and plasma HIV RNA, AIDS-
defining conditions, and deaths. Each cohort submits data
in a standardized format (http://www.hicdep.org/) to the
coordinating center. Ethics approval was granted by the
ethics committees of each of the participating cohorts
according to country-specific regulations.
The analyses presented here are based on data pooled in
September 2015 and were conducted on six cohorts
within the collaboration that contributed data on
genotypic drug-resistance testing conducted as part of
routine clinical care (AMACS from Greece, AIDS
Therapy Evaluation in the Netherlands, CoRIS from
Spain, Swiss HIV Cohort Study, UK CHIC/UK HIV
Drug Resistance Database, and UK Register of HIV
Seroconverters from the United Kingdom). The analyses
were restricted to individuals who met the following
eligibility criteria after 1999: age at least 18 years and
CD4þ cell count and HIV RNA measurements within 3
months of each other while AIDS free and ART naive.
Because in the early antiretroviral era ART combinations
were suboptimal and the drug-resistance testing uncom-
mon, we also restricted to individuals who entered a
cohort on or after 1 January 2000. Follow-up started at
baseline, defined as the earliest date that all eligibility
criteria were met, and ended at the earliest of detection of
acquired drug resistance, death, 12 months after the most
recent HIV RNA or CD4þ cell count laboratory
measurement, cohort-specific administrative censoring,
date of pregnancy when known, or initiation of an ART
combination not defined as ART (see below).
Treatment strategies
We defined initiation of combined ART as initiation of
combination of antiretroviral drugs including at least two
nucleoside reverse transcriptase inhibitors (NRTIs) and
either one or more protease inhibitors, one nonnucleo-
side reverse transcriptase inhibitor (NNRTI), one entry/
fusion inhibitor, or one integrase inhibitor. We compared
the following strategies: immediate ART initiation within
3 months of baseline, initiation within 3 months of a
CD4þ cell count less than 500 cells/ml or an AIDSealth, Inc. All rights reserved.
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count less than 350 cells/ml or an AIDS diagnosis [14].
Clinical guidelines recommend drug resistance testing at
all episodes of virological failure in ART-treated people
[5–8,15]. However, in clinical practice these tests are not
always performed. Therefore, to ensure that our estimates
reflect the real-world frequency of both drug resistance
testing and clinically identified acquired drug resistance,
none of the strategies imposed a drug resistance test at
virological failure. In sensitivity analyses (see below), we
considered an alternative strategy that imposed a drug
resistance test at each episode of virological failure.
Drug resistance
The outcome was clinically identified, acquired drug
resistance up to 7 years after baseline. Acquired drug
resistance was defined as predicted intermediate or high-
level resistance to any of the following antiretroviral drugs
in use during the study period: atazanavir, darunavir,
fosamprenavir, indinavir, lopinavir, nelfinavir, saquinavir,
tipranavir (protease inhibitors); lamivudine, emtricita-
bine, abacavir, didanosine, tenofovir, stavudine, zidovu-
dine (NRTI); nevirapine, efavirenz, etravirine, rilpivirine
(NNRTI). Resistance to Integrase Inhibitors (INI) was
not examined because it was collected only in one cohort
and even in this cohort it was very rare [16]. Predicted
resistance was derived using the Genotypic Resistance
Interpretation Algorithm, version 7.0 (HIVdb Program,
Stanford University, http://hivdb.stanford.edu). To min-
imize the inclusion of transmitted drug resistance in the
outcome definition, mutations conferring resistance to a
drug class the person had never taken or genotypic tests
on blood samples collected within 6 months after ART
initiation were not considered as acquired drug resistance.
Statistical methods
Because standard statistical methods cannot appropriately
adjust for time-varying confounders affected by prior
treatment [17,18], we used the parametric g-formula to
adjust for the time-varying confounders CD4þ cell count,
HIV RNA level, AIDS, drug-resistance testing, and
treatment class (NNRTI versus non-NNRTI-based regime)
as well as for time-fixed confounders measured at baseline.
The parametric g-formula, a generalization of standardiza-
tion for time-varying treatments and confounders, [18–20]
estimates the risk of drug resistance that would have been
observed if all patients in the study had adhered to a
particular treatment initiation strategy and none had been
lost to follow-up, under the assumptions of no residual
confounding, no measurement error, and no model
misspecification [19,21]. The estimation procedure for
the HIV-CAUSAL collaboration has been described
elsewhere [20]. Briefly, the procedure has two steps. First,
parametric regression models are used to estimate the joint
distribution of the outcome, treatment, and time-varying
covariates conditional on previous treatment and covariate Copyright © 2018 Wolters Kluwehistory. Second, a Monte Carlo simulation using the above
estimates is run to simulate the distribution of the
postbaseline outcomes and time-varying covariates sepa-
rately under each ART initiation strategy.
For the first step, we fit separate binary logistic regression
models for time-varying indicators of genotypic testing,
detection of an acquired drug resistance after a test, death,
AIDS-defining condition, ART initiation, measurement
of CD4þ cell count, measurement of HIV RNA, and
linear regression models for CD4þ cell count and HIV-
RNA on the natural logarithm scale. All regression models
included the following covariates: the most recent value of
these time-varying variables using cubic splines, time since
last CD4þ cell count and HIV-RNA measurements, and
the following baseline variables: CD4þ cell count (<100,
100–199,200–349,350–499, 500 cells/ml), HIV RNA
level (<10 000,10 000–100 000, >100 000 copies/ml),
age (<35,35–49,50 years), sex, mode of HIVacquisition
(heterosexual, homo/bisexual, IDUs, or other/unknown),
calendar year (2000–2004, 2005–2010, 2011–2015),
testing for transmitted drug resistance (i.e., testing done
before ART initiation and within 12 months of baseline),
geographical origin (Western countries, Sub-Saharan
Africa, other, unknown), ethnicity (White, Black,
unknown), and cohort. All models also included an
interaction term for number of months since ART
initiation. The g-formula estimates of risk in the presence
of competing risks (death) can be interpreted as an
extension of the subdistribution cumulative incidence
function to the setting of time-varying treatments and
confounders [19]. We used a nonparametric bootstrap
procedure based on 500 samples to obtain percentile-based
95% confidence intervals (CIs).
Like all regression-based methods, the parametric
g-formula relies on correct model specification. To
explore the validity of our parametric assumptions, we
compared the observed means of the outcome and time-
varying covariates with those predicted by our models.
The time-varying means predicted by our models under
observed ART initiation were similar to the observed
means in the original data (Appendix Figure, http://
links.lww.com/QAD/B186). All analyses were con-
ducted with the publicly available SAS macro g-formula
(http://www.hsph.harvard.edu/causal/software/).
We conducted subgroup analyses in individuals with
baseline CD4þ more than 500 cells/ml (because
treatment effectiveness may depend on the initial
CD4þ cell count), individuals with baseline date at or
after 1 January 2005 (because some study participants
started antiretroviral combinations different from those in
current use), and individuals originating from Sub-
Saharan Africa (because patterns of acquired drug
resistance and testing might differ by geographical origin
[22] because of different HIV subtype and patterns of
treatment adherence).r Health, Inc. All rights reserved.
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The uptake of drug-resistance testing was relatively low in
our cohorts, even though HIV guidelines during the
study period recommended testing at every episode of
virological failure. Although this low uptake is consistent
with previous reports from high-income countries [23],
it may be partly explained by under ascertainment of
drug-resistance testing in our cohorts. We, therefore,
conducted two analyses to explore the sensitivity of
our results to underascertainment. First, we estimated the
7-year risk of acquired drug resistance if a drug-resistance
test had been conducted at each episode of virological
failure. Second, we estimated the 7-year risk of drug
resistance under the assumption that acquired drug
resistance was present at every episode of virological
failure. Virological failure was defined as the second of
two consecutive HIV RNA at least 400 copies/ml
measured at least 6 months after ART initiation [7]
preceded by a HIV RNA50 copies/ml or less.
Our estimates would be confounded if the decision to test
for drug resistance depended on treatment adherence, a Copyright © 2018 Wolters Kluwer H
Table 1. Baseline characteristics of the 50 981 included individuals, HIV
Baseline characteristics Eligible Initi
CD4þ cell count (cells/ml)
<100 4021 (8%)
100–200 4820 (9%)
200–350 11581 (23%)
350–500 12557 (25%)
>500 18002 (35%)
HIV RNA (copies/ml)
<10000 14491 (28%)
10000–100000 22670 (44%)
>100000 13820 (27%)
Sex
Male 40933 (80%)
Female 10048 (20%)
Age (years)
<35 25001 (41%)
35–50 21015 (10%)
>50 4965 (31%)
Mode of HIV acquisition
Heterosexual 15 743 (31%)
Homo/bisexual 29 482 (58%)
IDU 2279 (4%)
Other/unknown 3477 (7%)
Calendar year
2000–2004 14894 (29%)
2005–2009 19254 (38%)
2010–2015 16833 (33%)
Region of origin
Western countries 19 751 (39%)
Sub-Saharan Africa 2233 (4%)
Rest of the world 4407 (9%)
Unknown 24590 (48%)
Ethnicity
White 20 714 (41%)
Black 7991 (16%)
Other/unknown 22276 (44%)
Testing for transmitted drug resistance
No 28820 (56%)
Yes 22 161 (43%)
Overall 50 981 (100%)
ART, antiretroviral therapy; IQR, interquartile range.type of information that is usually not captured in HIV
cohort data. We, therefore, compared the estimates with
and without adjustment for time-varying, self-reported
adherence (never missed a dose in the previous 4 weeks
versus missed at least one dose) in the Swiss HIV Cohort
Study, the only cohort collecting this information
longitudinally [24,25].
Finally, to examine the impact of heterogeneity by cohort
in the patterns of drug-resistance testing and the
collection of genotyping resistance, we reran the analyses
excluding each of the six cohorts one at a time.Results
Table 1 shows the baseline characteristics of the 50 981
eligible individuals: 80% were men, 71% started follow-up
after 2004; median [interquartile range (IQR)] CD4þ cell
count and age at baseline were 405 (256, 580) cells/ml and
35 (29, 42) years, respectively. 18 002 (25%) individuals had
a CD4þ cell count more than 500 cells/ml at baseline. Aealth, Inc. All rights reserved.
-CAUSAL collaboration 2000–2015.
ators of ART (%) Median (IQR) follow-up time, years
86 3.8 (1.9, 6.8)
86 4 (2.0, 6.8)
76 3.9 (2.0, 6.5)
60 3.7 (1.9, 6.0)
44 3.3 (1.7, 5.6)
48 3.5 (1.8, 5.9)
64 3.8 (1.9, 6.3)
77 3.7 (1.8, 6.4)
63 3.7 (1.9, 6.2)
62 3.5 (1.8, 6.3)
57 3.3 (1.8, 5.8)
67 3.9 (2.1, 6.5)
75 3.7 (2.0, 6.3)
65 3.7 (1.8, 6.3)
63 3.8 (2.0, 6.3)
54 2.5 (1.3, 5.4)
59 3.3 (1.8, 5.5)
61 6.7 (3.3, 9.8)
67 4.5 (2.7, 6.0)
59 1.9 (1.2, 2.8)
68 3.8 (2.0, 6.3)
66 3.7 (1.8, 6.2)
61 3.3 (1.8, 5.8)
59 3.6 (1.8, 6.3)
63 3.9 (2.0, 6.7)
59 3.4 (1.8, 5.9)
64 3.5 (1.8, 5.9)
63 3.4 (1.8, 6.5)
63 3.8 (2.1, 6.0)
62 3.7 (1.9, 6.5)
Immediate initiation of antiretroviral treatment Lodi et al. 331total of 22 161 individuals (43%) were tested for transmitted
drug resistance while ART-naive and within 12 months of
baseline; transmitted drug resistance was detected in 6.1%
of these tests.
During a follow-up of 204 914 person-years, 31 969
(63%) individuals initiated ART at a median CD4þ cell
count of 270 cells/ml (177, 369) and 5 (1, 20) months after
baseline. Of these, 3207 (10%) initiated ARTwith CD4þ
cell count more than 500 cells/ml. The most common
initial ART combinations were NNRTI and two NRTI
(64%) and boosted protease inhibitors and two NRTI
(29%). Initial combinations containing INI and two
NRTI, unboosted protease inhibitors and two NRTI
and three NRTI were uncommon (3, 3, and 1%,
respectively). The presence of acquired drug resistance
was tested for in 2672 samples with median (IQR) HIV
RNA of 2475 (236, 33 434) copies/ml. Factors associated
with higher rates of testing were female sex, heterosexual
HIV transmission group, IDU, and younger age at Copyright © 2018 Wolters Kluwe
Table 2. Tests for acquired drug resistance and number of episodes of vi
months after antiretroviral therapy initiation.
Tests for acquired
drug resistance
Te
Baseline characteristics N Tests/1000 person-years N
Overall 2672 20.1 794
CD4þ cell count (cells/ml)
<100 449 28.9 207
100–200 433 23.5 138
200–350 750 19.3 216
350–500 487 15.8 111
>500 553 19.1 122
HIV RNA (copies/ml)
<10000 435 16 111
10000–100000 1117 18.4 338
>100000 1120 25 345
Sex
Male 1959 18.1 574
Female 713 29 220
Age (years)
18–35 1318 23.9 382
35–50 1136 18.3 351
>50 218 14 61
Mode of HIV acquisition
Heterosexual 1087 25.8 367
Homo/bi-sexual 1326 16.9 337
IDU 127 30.1 36
Other/unknown 132 17 54
Calendar year
2000–2004 1403 24 486
2005–2009 1069 19 264
2010–2015 200 11.1 44
Region of origin
Western countries 524 9.2 181
Sub-Saharan Africa 159 28.2 65
Rest of the world 137 13.6 55
Unknown 1852 30.9 493
Ethnicity
White 1288 22.1 312
Black 727 38.1 245
Other/unknown 657 11.9 237
Testing for transmitted drug resistance
No 1478 19 508
Yes 1194 11.1 286
HIV-CAUSAL collaboration 2000–2015.
aVirological failure was defined as the second of two consecutive HIV RNbaseline (Table 2). The rate of drug-resistance testing
declined steadily over time. Similar associations and trends
by baseline characteristics and calendar period were found
for the rates of detection of drug resistance and of
virological failure (Table 2). Cohorts differed in the rates
of drug resistance testing and of virological failure
(Appendix Table 1, http://links.lww.com/QAD/B186).
There were 1874 episodes of virological failure, of which
617 (33%) were followed by a drug-resistance test within
12 months. The proportion of episodes of virological
failure followed by a test increased from 20% in 2000–
2004 to 37 and 36% in 2005–2009 and 2010–2015,
respectively. Resistance to any drug was detected in 794
(30%) samples. Resistance to NNRTI, NRTI and
boosted protease inhibitors was detected in 512 (19%),
576 (22%), and 67 (3%) samples, respectively.
The observed risk of acquired drug resistance was 2.7% at 7
years after baseline. The estimated 7-year risk (95% CI) ofr Health, Inc. All rights reserved.
rological failurea and corresponding rates per 1000 person-years 6
sts detecting acquired
drug resistance
Virological failure
episodesa
Tests/1000 person-years N Episodes/1000 person-years
6 1874 14.1
13.3 227 14.8
7.5 254 13.8
5.6 546 14.1
3.6 403 13
4.2 404 15.3
4.1 425 15.6
5.6 803 13.2
7.7 646 14.4
5.3 1300 12
9 574 23.4
6.9 953 17.3
5.7 790 12.8
3.9 131 8.4
8.7 778 18.7
4.3 864 11
8.5 120 28.5
7 102 13.2
8.3 1104 18.9
4.7 609 10.8
2.4 162 9
3.2 602 10.6
11.5 128 22.7
5.4 109 10.8
8.2 1035 17.2
5.4 849 14.6
12.8 461 24.2
4.3 564 10.2
6.6 1200 15.5
5.2 674 12.2
A 400 copies/ml preceded by HIV RNA 50 copies/ml.
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Fig. 1. Risk of acquired drug resistance up to 7 years after
baseline by ART initiation strategy. ART, antiretroviral ther-
apy. HIV-CAUSAL collaboration 2000–2015.acquired drug resistance was 3.2% (2.8, 3.5) for immediate
ART initiation, 3.1% (2.7, 3.3) for initiation at CD4þ less
than 500 cells/ml, and 2.8% (2.5,3.1) for initiation at CD4þ
less than 350 cells/ml. Compared with immediate
initiation, the risk difference (95% CI) was 0.13%
(0.22, 0.06) under initiation at CD4þ less than 500
cells/ml, and 0.37% (0.52, 0.22) under initiation at
CD4þ less than 350 cells/ml (Fig. 1 and Table 3).
When restricting the analyses to individuals with baseline
in 2005–2015, the estimated 7-year risk (95% CI) of
acquired resistance was 1.9% (1.8, 2.5) for immediate
ART initiation, 1.9% (1.7,2.4) for initiation at CD4þ less
than 500 cells/ml, and 1.8% (1.7,2.2) for initiation at
CD4þ less than 350 cells/ml. When the analyses were
restricted to individuals with baseline CD4þ more than
500 cells/ml the 7-year risk estimates were 1.6% (1.2, 2.3),
1.9% (1.4, 2.4), and 1.6% (1.2,2.1) for immediate
initiation and initiation with CD4þ cell count less than
500 cells/ml and CD4þ cell count less than 350 cells/ml,
respectively. Under immediate ART initiation the
estimated 7-year risk of acquired drug resistance was Copyright © 2018 Wolters Kluwer H
Table 3. Seven-year risk of acquired drug resistance and risk difference b
Inclusion criteria ART initiation s
All patients (N¼50981) Immediate
<500 cells/ml
<350 cells/ml
Baseline in calendar years 2005–2015 (N¼36087) Immediate
<500 cells/ml
<350 cells/ml
Baseline CD4þ cell count >500 cells/ml (N¼18002) Immediate
<500 cells/ml
<350 cells/ml
Individuals with Sub-Saharan Africa as Immediate
region of origin (N¼2233) <500 cells/ml
<350 cells/ml
HIV-CAUSAL collaboration 2000–2015. ART, antiretroviral therapy; CI, c4.4% (3.8, 5.0) when we imposed a drug-resistance test at
each episode of virological failure, and 10.9% (10.1, 11.4)
when we assumed that every instance of virological failure
was because of acquired drug resistance (Table 4). Results
did not materially change in the subgroup analyses
sequentially excluding each of the cohorts (Appendix
Table 2, http://links.lww.com/QAD/B186). In the Swiss
HIV Cohort Study data, the estimates of risk under all
strategies adjusting for self-reported adherence were
similar to the estimates not adjusting for adherence (risk
difference <0.4%).Discussion
In HIV-positive individuals receiving routine clinical care
in Europe, we estimated that the risk of acquired drug
resistance was similar under immediate and delayed ART
initiation. Compared with ART initiation with CD4þ
less than 500 cells/ml or AIDS and CD4þ less than 350
cells/ml or AIDS, immediate ART initiation increased the
7-year risk of acquired drug resistance by only 0.13 and
0.37%, respectively. The estimated 7-year risk of clinically
identified acquired drug resistance was approximately 3%
under all ART initiation strategies. These risks and risk
differences were even lower in individuals with initial
CD4þ cell count more than 500 cells/ml and individuals
who entered the study after 2004.
To our knowledge, this is the first study to estimate the
public health impact of immediate ART initiation on the
risk of acquired drug resistance. Previous studies found
that higher CD4þ cell count at ART initiation was
associated with lower risk of resistance [10–13]. Unlike in
these studies, we quantified the risk of drug resistance
since baseline, a proxy of entry into HIV care, rather than
ART initiation. Our estimates of risk take into account
that immediate initiation implies longer exposure to ART
and thus increased chance of drug resistance and the risk
of acquiring drug resistance before ART initiation is zero.
Our findings indicate that it is unlikely that the clinical
benefits of early ART initiation demonstrated byealth, Inc. All rights reserved.
y antiretroviral therapy initiation strategy and inclusion criteria.
trategy Risk at 7 years, % (95% CI) Risk difference (95% CI)
3.2 (2.8, 3.5) 0 (Ref.)
3.1 (2.7, 3.3) 0.13 (0.22, 0.06)
2.8 (2.5, 3.0) 0.37 (0.52, 0.22)
1.9 (1.8, 2.5) 0 (Ref.)
1.9 (1.7, 2.4) 0.08 (0.21, 0.04)
1.8 (1.7, 2.2) 0.15 (0.39, 0.02)
1.6 (1.2, 2.3) 0 (Ref.)
1.9 (1.4, 2.4) 0.22 (0.18, 0.48)
1.6 (1.2, 2.1) 0.08 (0.62, 0.36)
6.5 (4.2, 9.3) 0 (Ref.)
6.2 (4.2, 9.1) 0.27 (0.85, 0.11)
5.6 (3.7, 8.7) 0.90 (1.67, 0.00)
onfidence interval.
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Table 4. Sensitivity analyses to examine the role of potential underascertainment of drug resistance testing. Estimated 7-year risk of acquired
drug resistance and risk difference by antiretroviral therapy initiation strategy.
Outcome ART initiation strategy Risk at 7 years, % (95% CI) Risk difference (95% CI)
Acquired drug resistance under the observed data Immediate 3.2 (2.8, 3.5) 0 (Ref.)
<500 cells/ml 3.1 (2.7, 3.3) 0.13 (0.22, 0.06)
<350 cells/ml 2.8 (2.5, 3.0) 0.37 (0.52, 0.22)
Acquired drug resistance assuming a drug Immediate 4.4 (3.8, 5.0) 0 (Ref.)
resistance test at every virological failurea episode <500 cells/ml 3.8 (3.3, 4.3) 0.60 (0.71, 0.44)
<350 cells/ml 3.1 (2.8, 3.6) 1.27 (1.47, 0.99)
Virological failurea episode Immediate 10.9 (10.1, 11.4) 0 (Ref.)
<500 cells/ml 9.3 (8.6, 9.8) 1.58 (1.74, 1.39)
<350 cells/ml 7.5 (6.9, 7.8) 3.42 (3.69, 3.07)
HIV-CAUSAL collaboration 2000–2015. ART, antiretroviral therapy; CI, confidence interval.
aVirological failure was defined as the second of two consecutive HIV RNA 400 copies/ml preceded by HIV RNA 50 cells/ml.randomized clinical trials [1,2] and observational studies
[26–30] will be lessened by development of acquired drug
resistance. In high-income countries, the need for second-
line treatments because of the development of acquired
drug resistance will increase only slightly under the new
ART initiation guidelines [5–8]. In particular, our findings
indicate that in a hypothetical cohort of 1000 patients,
immediate initiation would imply only four additional
cases in need of second-line treatment over a 7-year period
compared to initiation with CD4þ cell count less than 350
cells/ml or AIDS. Moreover, because of the increasing use
of antiretroviral treatments associated with low drug
resistance such as INI and new generation protease
inhibitors, which were underrepresented in our data, we
expect this increase to be even lower in the longer term.
Further, the low risk of acquired drug resistance after 2004
indicates that acquired drug resistance is becoming a rare
phenomenon in Europe, though higher among individuals
born in Sub-Saharan Africa. This is compatible with
previous findings from the Swiss HIV Cohort Study
[22,31] and generalizes them to other European countries
with similar access to health care.
As in previous studies aimed at estimating the compara-
tive effectiveness of immediate ART initiation [27], we
analyzed the data both including all patients regardless of
initial CD4þ cell count (to estimate the public health
impact) and including only patients with high CD4þ cell
count at baseline (to estimate the effectiveness in this
particular subgroup). The low risk of drug resistance in
the subgroup of individuals with baseline CD4þ cell
count more than 500 cells/ml alleviates the concern that
individuals who are diagnosed with HIV while asymp-
tomatic might be less likely to adhere to treatment.
International and national HIV guidelines recommend
testing for transmitted drug resistance in all ART-naı¨ve
individuals and testing for acquired drug resistance in
ART-treated people after all episodes of virological
failure. Despite these recommendations only 43% of the
people included in our study were known to be tested for
transmitted drug resistance and only 33% of virological
failure episodes were known to be followed by an Copyright © 2018 Wolters Kluweacquired drug resistance test. Our estimates were,
however, robust under different scenarios of potential
underascertainment of acquired drug resistance.
The main strengths of our study are the large sample size
of over 50 000 individuals and the setting in HIV clinics in
Europe that are considered representative of routine
clinical practice [32]. Care should be taken with
generalizing our results to resource-limited settings
because of the differences in the HIV epidemics, and
availability of viral load monitoring, of drug-resistance
testing facilities, and of second and third-line therapy.
This study has several limitations. First, the validity of our
estimates relies on the assumption that all factors that
influenced the decision to initiate ART and the risk of
developing drug resistance were adjusted for. We expect
this assumption to approximately hold because we adjusted
for the most important factors used to decide whether to
initiate ART such as CD4þ cell count, HIV RNA, and
AIDS. Second, our methods require all models to be
correctly specified. This condition cannot be guaranteed,
but it seems plausible because our models resulted in
simulated datasets with distributions of outcome and time-
varying covariates similar to those in the original data.
Third, we could not estimate the long-term effect of
immediate initiation because approximately only 25% of
included patients had follow-up longer than 7 years.
Fourth, given that only half of the patients were genotyped
before ART initiation, some resistance-associated muta-
tions may, in fact, have been transmitted. It is, therefore,
possible that our estimates of risk of acquired drug
resistance are somewhat pessimistic. Finally, only a small
proportion of patients initiated treatment with INI, an
ARTregimen currently recommended as first-line therapy,
therefore, we could not appropriately assess drug resistance
for this drug class. However, according to recent reports,
drug resistance to INI is very rare and INI-treated patients
exhibit low rates of virological failure [16,31].
In conclusion, the risk of acquired drug resistance after
immediate ART initiation, the currently recommended
strategy for ART initiation, is very small and notr Health, Inc. All rights reserved.
334 AIDS 2018, Vol 32 No 3materially larger than if treatment is deferred. Therefore,
it is unlikely that the benefits of immediate ART
initiation will be compromised by development of
acquired drug resistance in high-income countries and
that immediate initiation will imply a substantial increase
in need of second-line treatments. Continual efforts
should be made to monitor trends in transmitted drug
resistance and acquired drug resistance in high and low-
income countries.
In summary, we estimated and compared the risk of
acquired drug resistance under immediate initiation (the
currently recommended ART initiation strategy) and
CD4þ cell count-based strategies. Immediate initiation
increased the risk of drug resistance, but the magnitude of
the change were very small.Acknowledgements
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